Our mission is to support transformational companies and drive innovation in life sciences
History
Mianus Capital (formerly Keylian Asset Management) was founded in 2015 in New York City, with an office in Shanghai. Since 2019, we have specialized in venture investing in healthcare and life sciences.
Our distinct advantage stems from a strategic collaboration with MERIT CRO, Inc., a global provider of technology and service solutions for clinical trials conducted by pharmaceutical and biotech companies. This partnership with an “insider” of global drug development ecosystem provides Mianus Capital a powerful platform for high-quality deal sourcing, along with access to extensive scientific, clinical, and commercial expertise.Â
Venture Capital
We collaborated with our strategic partner MERIT CRO, Inc. to launch our inaugural VC fund focusing on ophthalmology to drive early-stage innovation to significantly improve people’s vision and quality of life. MERIT CRO is proud to be the market leader with a premier brand and unparalleled expertise in global ophthalmology clinical trials. MERIT CRO supports the fund with access to high-quality deal flow, vast domain expertise and resource to pursue investment opportunities in the global ophthalmology market. We have since expanded our investment across oncology, ophthalmology and other therapeutic areas mainly focusing on supporting early-stage innovative biotech companies.